Precigen (NASDAQ:PGEN) COO Rutul Shah Sells 32,739 Shares

Precigen, Inc. (NASDAQ:PGEN) COO Rutul Shah sold 32,739 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $6.86, for a total transaction of $224,589.54. Following the completion of the sale, the chief operating officer owned 465,012 shares of the company’s stock, valued at approximately $3,189,982.32. This trade represents a 6.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $7.23 on Friday. The company has a market capitalization of $2.58 billion, a PE ratio of -6.95 and a beta of 1.02. The company has a quick ratio of 4.12, a current ratio of 4.58 and a debt-to-equity ratio of 2.15. The stock’s 50 day moving average price is $5.23 and its 200-day moving average price is $4.50. Precigen, Inc. has a twelve month low of $1.70 and a twelve month high of $7.26.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.06. The company had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.98 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.Precigen’s revenue was up 6322.7% compared to the same quarter last year. On average, equities analysts anticipate that Precigen, Inc. will post 0.05 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on PGEN. Zacks Research upgraded Precigen from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Citizens Jmp raised their price objective on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, May 14th. Wall Street Zen upgraded shares of Precigen from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Citigroup reiterated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Finally, HC Wainwright lifted their price target on Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.50.

Hedge Funds Weigh In On Precigen

A number of large investors have recently modified their holdings of PGEN. State of Wyoming bought a new stake in Precigen during the 1st quarter worth approximately $27,000. NBC Securities Inc. bought a new position in Precigen in the 4th quarter valued at $38,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Precigen during the 3rd quarter valued at $39,000. Royal Bank of Canada grew its position in shares of Precigen by 102.6% during the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,426 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new position in shares of Precigen in the third quarter worth $41,000. 33.51% of the stock is currently owned by institutional investors.

Key Headlines Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.